Mar 15, 2012 - 7:15 pm
John (and I) met with Dr. Hammers today after John's scan to see if the HDIL2 had been successful. He said the scan reflected a mixed response, with most of his lung mets showing some growth, but one met showing a slight reduction. So--bottom line--no more HDIL2. As way of history, John had received 14 doses in the first round and 10 in the second during January/February 2012.
Dr. Hammers then started talking about a MDX 1106/TKI clinical trial. It's a phase I trial/dose escalation phase. He is recommending John for the trial but, as I think Fox told us, the screening process is quite involved and can take some time. The study itself is to determine if MDX1106 (BMS-936558) can be safely given with sunitinib or pazopanib. Will keep you posted.